HOME >> MEDICINE >> NEWS
Iressa news backgrounder

It is a drug suffused in promise, a next-generation therapy that has shown glimmers of powerful potential. Iressa is the kind of treatment that oncologists dream of - a pill that can be swallowed once a day, a non-toxic therapy that causes few side effects. For 10 percent of patients who have tried it, people who have no other options left for them, Iressa seems to make the difference between life and death. Another 30 percent to 40 percent of patients who have used the drug have a better, if not a longer, life.

But for most patients, Iressa does not shrink their cancer. That fact has become a challenge to researchers at The University of Texas M. D. Anderson Cancer Center. They are dedicated to solving the central puzzle that Iressa, and similar other targeted therapies, pose - what are the cancers that may best respond, and which patients will benefit?

M. D. Anderson researchers have been at the forefront of testing Iressa, as well as a slew of other experimental drugs that target critical cancer cell pathways. They have been involved in all phases of clinical trials looking at the effectiveness of Iressa in common lung cancer, work that helped lead to federal Food and Drug Administration approval of the drug in early 2003 for use when standard therapy has not helped lung cancer patients.

Now, investigators at M. D. Anderson are testing Iressa in malignant brain cancer and are poised to study it in a number of cancers, including head and neck, breast, and prostate, along with further investigations in lung cancer.

"M. D. Anderson is one of the leading institutions in developing targeted therapies such as Iressa," says Frank Fossella, M.D., professor in the Department of Thoracic/Head and Neck Medical Oncology, who has treated many lung and other head and neck cancers where it has shown tantalizing benefit.

"So far, Iressa has been a good news, bad news story. The response rates are not as high as we would have liked
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
16-Oct-2003


Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Gene mutations predict which lung cancers will respond to Iressa
2. Iressa news backgrounder: Testing of smart drug expands at M. D. Anderson Cancer Center
3. Chemoprevention backgrounder: Working for a future of cancer chemoprevention
4. Cancer gene therapy news backgrounder: New ideas fuel next generation gene therapy research
5. Cancer markers news backgrounder: Future of cancer diagnosis, treatment lies in tumor barcode

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Iressa news backgrounder

(Date:10/25/2014)... York (PRWEB) October 25, 2014 ... lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston ... in U.S. District Court, Southern District of West ... Judgment on Punitive Damages in a group of ... a ruling issued on October 21st, U.S. District ...
(Date:10/25/2014)... 25, 2014 Limbkeepers® announced today that ... Innovations with Ed Begley Jr, airing 1st QTR 2015 ... In this episode, Innovations will focus on Limbkeepers® non ... fragile, thinning skin on arms, hands, and legs from ... these versatile products, which help reduce injuries, allow for ...
(Date:10/25/2014)... By Steven Reinberg ... -- The virus that causes common cold sores -- herpes ... studies by Swedish researchers suggest. In fact, being a ... risk of Alzheimer,s disease, the researchers found. "The ... common dementia disorder is a breakthrough," said lead researcher Dr. ...
(Date:10/25/2014)... -- Researchers who discovered antibiotics in farmed and ... concern. The use of antibiotics in animals, ... contribute to the development of antibiotic-resistant bacteria that ... the study. Each year in the United ... and kill about 23,000, according to the Infectious ...
(Date:10/25/2014)... Current osteoporosis screening guidelines and tools fail to ... osteoporosis-related fractures, a new study says. "If ... that help us accurately predict who will suffer ... these at-risk people for preventive measures," study author ... division of general internal medicine and health services ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
(Date:10/22/2014)... HAMILTON, N.J. , Oct. 22, 2014 ... CLIA-certified, CAP-accredited laboratory which specializes in high ... that it is now offering new Cystic ... including next- generation DNA sequencing platforms. ... a genetically inherited multisystem disorder that affects ...
(Date:10/22/2014)... Antigen Discovery Inc. (ADi), a privately held ... the receipt of a National Institutes of Health (NIH) ... Institute of Dental and Craniofacial Research (NIDCR). The one-year ... Protein Microarray Chip, which will contain every protein in ... in the development of safe and effective vaccines and ...
(Date:10/22/2014)... -- AVACEN Medical announced today that its AVACEN 100 ... by the U.S. Food and Drug Administration. This clearance ... Internet for: the temporary relief of joint pain ... sprains . Logo - http://photos.prnewswire.com/prnh/20141021/153513 ... a sophisticated medical device incorporating over 3,000 firmware instructions ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests 2Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
Cached News: